First-line serologic screening test for suspected Lyme disease. Positive or equivocal results must be confirmed by immunoblot.
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
CSF. Contaminated, heat-inactivated, hemolyzed, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
|0.99 LIV or less||Negative - Antibody to B. burgdorferi not detected.|
|1.00-1.20 LIV||Equivocal - Repeat testing in 10-14 days may be helpful.|
|1.21 LIV or greater||Positive - Probable presence of antibody to B. burgdorferi detected.|
No compliance statements are in use for this test.
Once this test is performed, if:
a) Negative - no further testing is done;
b) Positive or equivocal - immunoblot testing will be performed on the original sample upon receiving a request. Sample will be held for 30 days only.
Current CDC recommendations for the serologic diagnosis of Lyme disease are to screen with a polyvalent ELISA test and confirm equivocal and positive results with Immunoblot. Both IgM and IgG Immunoblots should be performed on specimens less than 4 weeks after appearance of erythema migrans. Only IgG Immunoblot should be performed on specimens greater than 4 weeks after the disease onset. IgM Immunoblot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease. Please submit requests for appropriate Immunoblot testing within 10 days.
|Component Test Code*||Component Chart Name||LOINC|
|0050216||Borrelia burgdorferi Abs, Total by ELISA||5060-9|
- Lyme Antibodies Detection
- Lyme Disease
- Lyme Disease Ab ELISA